A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.